Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Carbohydrate-Rich Fraction of Aloe vera (L.) Burm.f. Extract Mitigates Bone Loss and Improves Metabolic Disturbance in Estrogen-Deficient Rats

Suntornsaratoon P., Bulanawichit W., Chimlek W., Saeten W., Sorndech W., Sumsakul W.

Animal Study on Type 2 Diabetes, published in Pharmacol Res Perspect (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Pharmacol Res Perspect (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40673869
PMCID
PMC12269533
DOI
10.1002/prp2.70148
Citations
1

Abstract (original English)

Aloe vera (L.) Burm.f., (AE) herb has been shown to have osteogenic, anti-diabetic, and prebiotic activities in animal and human studies. Postmenopausal women generally exhibit massive bone loss, impaired intestinal calcium absorption, obesity-related insulin resistance, and fat accumulation in the liver. It was possible that the AE herb may have a potential as a remedy for bone and metabolic disturbances associated with estrogen deficiency. Sham and ovariectomized rats were divided into 2 subgroups, that is, receiving daily administration of distilled water or 50 or 100 mg/kg of AE via either oral administration (p.o.) or intraperitoneal injection (i.p.) for 8 and 12 weeks. Nine weeks after ovariectomy, rats developed metabolic disturbances, as evidenced by obesity, impaired glucose tolerance, and high serum cholesterol levels. AE supplementation, either by p.o. or i.p., alleviated metabolic aberrations by improving glucose tolerance, reducing body weight, and decreasing fat deposition by increasing serum insulin levels. Furthermore, AE supplementation restored ovariectomy-associated calcium malabsorption to that of sham. At week 12 post-ovariectomy, massive bone loss was observed at trabecular-rich regions. Daily AE supplementation at 50 mg/kg for 12 weeks, but not 8 weeks, significantly increased BMD and BMC compared with those of sham. Additionally, AE enhanced bone formati

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsRatsRats, Sprague-DawleyAloeInsulin ResistancePlant ExtractsEstrogensOvariectomyBone DensityFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research